Rare copy number variation in autoimmune Addison's disease

Front Immunol. 2024 Mar 18:15:1374499. doi: 10.3389/fimmu.2024.1374499. eCollection 2024.

Abstract

Autoimmune Addison's disease (AAD) is a rare but life-threatening endocrine disorder caused by an autoimmune destruction of the adrenal cortex. A previous genome-wide association study (GWAS) has shown that common variants near immune-related genes, which mostly encode proteins participating in the immune response, affect the risk of developing this condition. However, little is known about the contribution of copy number variations (CNVs) to AAD susceptibility. We used the genome-wide genotyping data from Norwegian and Swedish individuals (1,182 cases and 3,810 controls) to investigate the putative role of CNVs in the AAD aetiology. Although the frequency of rare CNVs was similar between cases and controls, we observed that larger deletions (>1,000 kb) were more common among patients (OR = 4.23, 95% CI 1.85-9.66, p = 0.0002). Despite this, none of the large case-deletions were conclusively pathogenic, and the clinical presentation and an AAD-polygenic risk score were similar between cases with and without the large CNVs. Among deletions exclusive to individuals with AAD, we highlight two ultra-rare deletions in the genes LRBA and BCL2L11, which we speculate might have contributed to the polygenic risk in these carriers. In conclusion, rare CNVs do not appear to be a major cause of AAD but further studies are needed to ascertain the potential contribution of rare deletions to the polygenic load of AAD susceptibility.

Keywords: Addison’s disease; BCL2L11; LRBA; autoimmune; copy number variation; rare deletions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / genetics
  • Addison Disease* / genetics
  • Addison Disease* / pathology
  • DNA Copy Number Variations
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Polymorphism, Single Nucleotide

Substances

  • LRBA protein, human
  • Adaptor Proteins, Signal Transducing

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants (to SJ) Helse Vest’s Open Research Grant (grants #912250 and F-12144), the Novo Nordisk Foundation (grant NNF19OC0057445) and the Research Council of Norway (grant #315599); MV is supported by the Research Council of Norway (project #301178). The study was further supported by the Western Norway Health Authorities (ESH and ASBW). SB and DE received support from the ALF-agreement between the Swedish government and the county councils.